Literature DB >> 9559815

Comparative in vitro killing activities of meropenem, imipenem, ceftriaxone, and ceftriaxone plus vancomycin at clinically achievable cerebrospinal fluid concentrations against penicillin-resistant Streptococcus pneumoniae isolates from children with meningitis.

F Fitoussi1, C Doit, K Benali, S Bonacorsi, P Geslin, E Bingen.   

Abstract

The activities of meropenem, imipenem, ceftriaxone, and vancomycin were evaluated against 80 penicillin-susceptible and -resistant Streptococcus pneumoniae strains. Meropenem, imipenem, ceftriaxone, and vancomycin MICs at which 90% of the isolates are inhibited were 0.5, 0.25, 1, and 0.25 microg/ml, respectively. Against penicillin-resistant strains, the best killing activity at cerebrospinal fluid concentrations was obtained with imipenem and ceftriaxone-vancomycin. However, while the killing activity of imipenem was significantly greater than that of meropenem, no significant difference was observed between the activities of meropenem and ceftriaxone-vancomycin.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9559815      PMCID: PMC105574          DOI: 10.1128/AAC.42.4.942

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  26 in total

1.  Effect of antibiotics carry-over on bacterial counting by 'spiral plating'.

Authors:  E Yourassowsky; M P Van der Linden; F Crokaert; Y Glupczynski
Journal:  J Antimicrob Chemother       Date:  1988-01       Impact factor: 5.790

2.  Delayed cerebrospinal fluid sterilization and adverse outcome of bacterial meningitis in infants and children.

Authors:  M H Lebel; G H McCracken
Journal:  Pediatrics       Date:  1989-02       Impact factor: 7.124

3.  Penetration of imipenem and cilastatin into cerebrospinal fluid of patients with bacterial meningitis.

Authors:  J Modai; D Vittecoq; J M Decazes; A Meulemans
Journal:  J Antimicrob Chemother       Date:  1985-12       Impact factor: 5.790

Review 4.  Management of meningitis caused by penicillin-resistant Streptococcus pneumoniae.

Authors:  M M París; O Ramilo; G H McCracken
Journal:  Antimicrob Agents Chemother       Date:  1995-10       Impact factor: 5.191

5.  Killing activity of cefpirome against penicillin-resistant Streptococcus pneumoniae isolates from patients with meningitis in a pharmacodynamic model simulating the cerebrospinal fluid concentration profile.

Authors:  F Fitoussi; C Doit; A Sandin; A Pechinot; A Kazmierczack; P Geslin; E Bingen
Journal:  Antimicrob Agents Chemother       Date:  1995-11       Impact factor: 5.191

6.  Killing kinetics of imipenem against penicillin-resistant Streptococcus pneumoniae.

Authors:  V Barakett; D Lesage; F Delisle; G Richard; J C Petit
Journal:  J Antimicrob Chemother       Date:  1994-05       Impact factor: 5.790

7.  Killing kinetics of meropenem against penicillin-resistant pneumococci.

Authors:  V Barakett; D Lesage; F Delisle; G Richard; J C Petit
Journal:  J Antimicrob Chemother       Date:  1996-12       Impact factor: 5.790

Review 8.  The challenge of penicillin-resistant Streptococcus pneumoniae meningitis: current antibiotic therapy in the 1990s.

Authors:  J S Bradley; W M Scheld
Journal:  Clin Infect Dis       Date:  1997-02       Impact factor: 9.079

9.  Efficacy of meropenem in experimental meningitis.

Authors:  K Nairn; G L Shepherd; J R Edwards
Journal:  J Antimicrob Chemother       Date:  1995-07       Impact factor: 5.790

10.  In vitro activities of cefotaxime, ceftriaxone, ceftazidime, cefpirome, and penicillin against Streptococcus pneumoniae isolates.

Authors:  A L Barry; S D Brown; W J Novick
Journal:  Antimicrob Agents Chemother       Date:  1995-10       Impact factor: 5.191

View more
  5 in total

1.  Killing activities of trovafloxacin alone and in combination with beta-lactam agents, rifampin, or vancomycin against Streptococcus pneumoniae isolates with various susceptibilities to extended-spectrum cephalosporins at concentrations clinically achievable in cerebrospinal fluid.

Authors:  F Fitoussi; C Doit; P Geslin; E Bingen
Journal:  Antimicrob Agents Chemother       Date:  1999-10       Impact factor: 5.191

2.  Impact of Antimicrobial Resistance on the Treatment of Invasive Pneumococcal Infections.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  2000-10       Impact factor: 3.725

3.  Experimental study of meropenem in the therapy of cephalosporin-susceptible and -resistant pneumococcal meningitis.

Authors:  E Force; F Taberner; C Cabellos; S Ribes; A Domenech; F Tubau; P F Viladrich; F Gudiol
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-04-02       Impact factor: 3.267

Review 4.  Management of infections due to antibiotic-resistant Streptococcus pneumoniae.

Authors:  S L Kaplan; E O Mason
Journal:  Clin Microbiol Rev       Date:  1998-10       Impact factor: 26.132

5.  Discovery and Characterization of Diazenylaryl Sulfonic Acids as Inhibitors of Viral and Bacterial Neuraminidases.

Authors:  Anja Hoffmann; Martina Richter; Susanne von Grafenstein; Elisabeth Walther; Zhongli Xu; Lilia Schumann; Ulrike Grienke; Christina E Mair; Christian Kramer; Judith M Rollinger; Klaus R Liedl; Michaela Schmidtke; Johannes Kirchmair
Journal:  Front Microbiol       Date:  2017-02-15       Impact factor: 5.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.